Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

SK bioscience wins patent lawsuit against Pfizer over pneumococcal vaccine in Korea: Gyeonggi-do, Republic of Korea Friday, May 23, 2025, 10:00 Hrs [IST] SK bioscience, a global i ...

Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

The U.S. Food and Drug Administration's advisory panel is set to vote on Thursday to recommend whether COVID-19 vaccines for ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

And the man’s mother in tears recalling her son, a Boston police officer whose death is at the heart of a trial gripping the nation. The first full day of testimony concluded on Wednesday.

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of ...

Moscicki previously served as the deputy center director for science operations at the FDA’s Center for Drug Evaluation and ...